Trends: The effects of the coverage gap on drug spending: A closer look at medicare part D

Health Affairs

Volumn 28, Issue 2, 2009, Pages

  Zhang, Yuting ^a   Donohue, Julie Marie ^a   Newhouse, Joseph P ^b   Lave, Judith R ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

AGED; ARTICLE; CAPITATION FEE; CHRONIC DISEASE; COMORBIDITY; CONSUMER; COPAYMENT; DEMOGRAPHY; DIABETES MELLITUS; DRUG UTILIZATION; HEALTH CARE COST; HEALTH INSURANCE; HYPERTENSION; MEDICARE; OUT OF POCKET SPENDING; PRESCRIPTION; PRESCRIPTION DRUG COVERAGE; RISK ASSESSMENT; COST; ECONOMICS; FEE; HUMAN; INSURANCE; STATISTICS; UNITED STATES;

DEDUCTIBLES AND COINSURANCE; HEALTH EXPENDITURES; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MEDICARE; MEDICARE PART D; PRESCRIPTION FEES; UNITED STATES;

EID: 66149190565     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.2.w317     Document Type: Article

References (12)

1. Dollar values for the coverage gap and catastrophic coverage region in subsequent years were indexed to increases in drug spending.
2. Medicare Payment Advisory Commission, Report to the Congress: Increasing the Value of Medicare, June 2006, http://www.medpac.gov/publications/ congressional-reports/Jun06-EntireReport.pdf (accessed 19 May 2008).
3. J. Hsu et al., "Medicare Beneficiaries' Knowledge of Part D Prescription Drug Program Benefits and Responses to Drug Costs," Journal of the American Medical Association 299, no. 16 (2008): 1929-1936.
4. MedPAC, A Data Book: Healthcare Spending and the Medicare Program, June 2008, http://www.medpac.gov/documents/Jun08DataBook-Entire-report.pdf (accessed 1 December 2008).
5. Henry J. Kaiser Family Foundation, "Medicare Fact Sheet: The Medicare Prescription Drug Benefit," November 2006, http://www.kff.org/ medicare/upload/7044-05.pdf (accessed 1 December 2008).
6. G.C. Pope et al., "Risk Adjustment of Medicare Capitation Payments Using the CMS-HCC Model," Health Care Financing Review 25, no. 4 (2004): 119-141. (Pubitemid 39201560)
7. Relative to other medical spending, prescription drug spending is highly persistent and therefore predictable to consumers. See M.V. Pauly and Y. Zeng, "Adverse Selection and the Challenges to Stand-Alone Prescription Drug Insurance," Frontiers in Health Policy Research 7 (2004): 55-74.
8. R.G. Frank and J.P. Newhouse, "Mending the Medicare Prescription Drug Benefit: Improving Consumer Choices and Restructuring Purchasing," April 2007, http://www.brookings.edu/papers/2007/04useconomics-frank.aspx (accessed 1 December 2008).
9. R.G. Frank and J.P. Newhouse, "Mending the Medicare Prescription Drug Benefit: Improving Consumer Choices and Restructuring Purchasing," April 2007, http://www.brookings.edu/papers/2007/04useconomics-frank.aspx. Ibid.
10. See, for example, D.P. Goldman et al., "Pharmacy Benefits and the Use of Drugs by the Chronically Ill," Journal of the American Medical Association 291, no. 19 (2004): 2344-2350;
11. and H.A. Huskamp et al., "The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending," New England Journal of Medicine 349, no. 23 (2003): 2224-2232. (Pubitemid 37485139)
12. Kaiser Family Foundation, "Medicare Prescription Drug Plans in 2008 and Key Changes since 2006: Summary of Findings," April 2008, http://kff.org/medicare/upload/7762.pdf (accessed 19 May 2008).